JP7849296B2 - Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体 - Google Patents

Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体

Info

Publication number
JP7849296B2
JP7849296B2 JP2022550891A JP2022550891A JP7849296B2 JP 7849296 B2 JP7849296 B2 JP 7849296B2 JP 2022550891 A JP2022550891 A JP 2022550891A JP 2022550891 A JP2022550891 A JP 2022550891A JP 7849296 B2 JP7849296 B2 JP 7849296B2
Authority
JP
Japan
Prior art keywords
methyl
tetrahydro
cycloalkyl
piperazine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022550891A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021173523A5 (https=
JP2023514750A (ja
JP2023514750A5 (https=
Inventor
チェン，イ
Original Assignee
グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド filed Critical グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド
Publication of JP2023514750A publication Critical patent/JP2023514750A/ja
Publication of JPWO2021173523A5 publication Critical patent/JPWO2021173523A5/ja
Publication of JP2023514750A5 publication Critical patent/JP2023514750A5/ja
Application granted granted Critical
Publication of JP7849296B2 publication Critical patent/JP7849296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022550891A 2020-02-24 2021-02-23 Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体 Active JP7849296B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062980700P 2020-02-24 2020-02-24
US62/980,700 2020-02-24
US202063053565P 2020-07-17 2020-07-17
US63/053,565 2020-07-17
PCT/US2021/019181 WO2021173523A1 (en) 2020-02-24 2021-02-23 Hot melt extruded solid dispersions containing a bcl2 inhibitor

Publications (4)

Publication Number Publication Date
JP2023514750A JP2023514750A (ja) 2023-04-07
JPWO2021173523A5 JPWO2021173523A5 (https=) 2024-03-04
JP2023514750A5 JP2023514750A5 (https=) 2024-03-04
JP7849296B2 true JP7849296B2 (ja) 2026-04-21

Family

ID=74875347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550891A Active JP7849296B2 (ja) 2020-02-24 2021-02-23 Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体

Country Status (10)

Country Link
US (1) US20230295183A1 (https=)
EP (1) EP4110298A1 (https=)
JP (1) JP7849296B2 (https=)
KR (1) KR20220158725A (https=)
CN (1) CN115484933B (https=)
AU (1) AU2021228622A1 (https=)
CA (1) CA3173041A1 (https=)
IL (1) IL295803A (https=)
MX (1) MX2022010410A (https=)
WO (1) WO2021173523A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442685A4 (en) 2021-12-06 2025-11-19 Hangzhou Healzen Therapeutics Co Ltd BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES
US11964990B2 (en) 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
CN115894495B (zh) * 2022-11-29 2024-08-09 大连理工大学 一种基于尿酸与苯硼酸衍生物复合晶体的纯有机室温磷光材料的制备方法
CN116236583A (zh) * 2023-03-30 2023-06-09 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用
CN116270660A (zh) * 2023-03-30 2023-06-23 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012529490A (ja) 2009-06-08 2012-11-22 アボット ゲーエムベーハー ウント カンパニー カーゲー Ｂｃｌ−２ファミリー阻害剤の経口投与用医薬剤形
JP2013540823A (ja) 2010-10-29 2013-11-07 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む固体分散体
JP2013544804A (ja) 2010-10-29 2013-12-19 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む溶融押出固体分散体
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2019040573A1 (en) 2017-08-23 2019-02-28 Newave Pharmaceutical Inc. Bcl-2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
EP2231159A1 (en) 2007-11-16 2010-09-29 Abbott Laboratories Method of treating arthritis
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
EP3333167A1 (en) * 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
US12220419B2 (en) * 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012529490A (ja) 2009-06-08 2012-11-22 アボット ゲーエムベーハー ウント カンパニー カーゲー Ｂｃｌ−２ファミリー阻害剤の経口投与用医薬剤形
JP2013540823A (ja) 2010-10-29 2013-11-07 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む固体分散体
JP2013544804A (ja) 2010-10-29 2013-12-19 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む溶融押出固体分散体
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2019040573A1 (en) 2017-08-23 2019-02-28 Newave Pharmaceutical Inc. Bcl-2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Christian Leuner et al.，"Improving drug solubility for oral delivery using solid dispersions"，European Journal of Pharmaceutics and Biopharmaceutics，2000年，Vol.50，p.47-60，DOI: 10.1016/s0939-6411(00)00076-X

Also Published As

Publication number Publication date
JP2023514750A (ja) 2023-04-07
WO2021173523A1 (en) 2021-09-02
CN115484933B (zh) 2026-03-31
EP4110298A1 (en) 2023-01-04
MX2022010410A (es) 2022-12-07
AU2021228622A1 (en) 2022-10-13
IL295803A (en) 2022-10-01
CA3173041A1 (en) 2021-09-02
KR20220158725A (ko) 2022-12-01
CN115484933A (zh) 2022-12-16
US20230295183A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
JP7849296B2 (ja) Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体
US12220419B2 (en) BCL-2 inhibitors
US11680072B2 (en) Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
TWI648261B (zh) 含細胞凋亡誘導劑之經熔融擠製的固體分散劑
US20220372042A1 (en) Condensed heterocycles as bcl-2 inhibitors
US20100297194A1 (en) Formulation for oral administration of apoptosis promoter
WO2021133817A1 (en) 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
EA037517B1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
HK40097437A (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
HK40033360B (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
HK40033360A (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260409